A Long-Term Study of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Sanofi
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier:
NCT02004704
First received: November 26, 2013
Last updated: July 23, 2014
Last verified: July 2014
  Purpose

The primary objective of this study is to obtain data regarding the ongoing safety of recombinant human acid sphingomyelinase (rhASM) in patients with acid sphingomyelinase deficiency (ASD) who are exposed to long-term treatment with rhASM

The secondary objectives of this study are to obtain data regarding the efficacy of rhASM and to characterize rhASM pharmacodynamics and pharmacokinetics following long-term administration.


Condition Intervention Phase
Sphingomyelin Lipidosis
Drug: GZ402665
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Long-Term Study to Assess the Ongoing Safety and Efficacy of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • All Adverse events and Serious Adverse Events [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: Yes ]
    Number of patients experience AE

  • Physical examinations [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: Yes ]
  • Clinical laboratory tests [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: Yes ]
  • Safety biomarkers [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: Yes ]
  • Immune response assessments [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: Yes ]
  • Vital signs, echocardiogram and electrocardiogram [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: No ]
  • Continuous heart rate monitoring by telemetry (in-patients visits) [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Spleen and Liver Volume [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: No ]
  • Pulmonary imaging and function tests [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: No ]
  • Exercise capacity by cycle ergometry [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: No ]
  • Hematology [ Time Frame: Baseline to Week 272 ] [ Designated as safety issue: No ]

Estimated Enrollment: 70
Study Start Date: December 2013
Estimated Study Completion Date: July 2021
Estimated Primary Completion Date: July 2021 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GZ402665
GZ402665 dose (0,3; 1,0 or 3,0 mg/kg body weight) once every 2 weeks for 5 years
Drug: GZ402665

Pharmaceutical form:Powder for concentrate for solution for infusion

Route of administration: intravenous infusion


Detailed Description:

One month screening + 60 months from the first dose + 30 to 37 days post study safety follow up

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria :

  • The patient has completed the treatment period of a previous study of rhASM with an acceptable safety profile.
  • Negative serum pregnancy test.
  • Patients must practice true abstinence or use 2 effective forms of contraception

Exclusion criteria:

  • The patient is breast-feeding.
  • ALT or AST >250 IU/L or total bilirubin >1.5 mg/dL.
  • The patient is unwilling or unable to abstain from the use of alcohol for 1 day prior to and 3 days after each rhASM infusion for the duration of the study.
  • The patient requires medications that may decrease rhASM
  • Any new condition or worsening of an existing condition which in the opinionof the Investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02004704

Contacts
Contact: For site information, send an email with site number to Contact-Us@sanofi.com

Locations
United States, New York
Investigational Site Number 840001 Recruiting
New York, New York, United States, 10029-6574
United Kingdom
Investigational Site Number 826001 Recruiting
London, United Kingdom, WC1N 3BG
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

No publications provided

Responsible Party: Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier: NCT02004704     History of Changes
Other Study ID Numbers: LTS13632, 2013-000051-40, U1111-1141-65868
Study First Received: November 26, 2013
Last Updated: July 23, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Brain Diseases, Metabolic, Inborn
Lipidoses
Niemann-Pick Diseases
Niemann-Pick Disease, Type A
Niemann-Pick Disease, Type C
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism Disorders
Metabolic Diseases
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Histiocytosis, Non-Langerhans-Cell
Histiocytosis
Lymphatic Diseases
Lysosomal Storage Diseases

ClinicalTrials.gov processed this record on August 19, 2014